Xencor Inc (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, announced yesterday its financial results for the full year ended 31 December 2018.
The company reported total revenue of USD40.6m in 2018 compared to USD46.2m in the 2017.
The firm posted research and development expenditures for 2018 at USD97.5m compared to USD71.8m in 2017. For the year ended 31 December 2018, net loss was USD70.4m, or USD1.31 on a fully diluted per share basis, compared to a net loss of USD38.5m, or USD0.82 on a fully diluted per share basis, for the same period in 2017. The company stated that increased loss for the year ended 31 December 2018 over amounts for the same period in 2017 is primarily due to increased spending in research and development and general and administrative in 2018.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca